| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6432948 | FONSECA BIOSCIENCES | Use of 7-(2-oxa-5,8-diazabicylco[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of heliobacter pylori infections and associated gastroduodenal diseases |
Apr, 2017
(7 years ago) | |
| US6133260 | FONSECA BIOSCIENCES | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases |
Apr, 2017
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993483 | FONSECA BIOSCIENCES | Compositions and methods for treating ophthalmic, octic, or nasal infections |
Jul, 2030
(6 years from now) | |
| US9119859 | FONSECA BIOSCIENCES | Methods for treating otic infections |
Jul, 2030
(6 years from now) | |
| US8536167 | FONSECA BIOSCIENCES | Methods for treating ophthalmic, otic, or nasal infections |
Aug, 2031
(7 years from now) | |
| US9504691 | FONSECA BIOSCIENCES | Finafloxacin suspension compositions |
Nov, 2033
(9 years from now) | |
Xtoro is owned by Fonseca Biosciences.
Xtoro contains Finafloxacin.
Xtoro has a total of 6 drug patents out of which 2 drug patents have expired.
Expired drug patents of Xtoro are:
- US6432948
- US6133260
Xtoro was authorised for market use on 17 December, 2014.
Xtoro is available in suspension/drops;otic dosage forms.
Xtoro can be used as treatment of acute otitis externa.
Drug patent challenges can be filed against Xtoro from 18 June, 2019.
The generics of Xtoro are possible to be released after 21 November, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 17, 2019 |
| Pediatric Exclusivity(PED) | Jun 17, 2020 |
Drugs and Companies using FINAFLOXACIN ingredient
NCE-1 date: 18 June, 2019
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS;OTIC
XTORO family patents
